Kura Oncology Welcomes New Director Michael Vasconcelles
Company Announcements

Kura Oncology Welcomes New Director Michael Vasconcelles

Kura Oncology ( (KURA) ) has provided an update.

Kura Oncology, Inc. has appointed Michael J. Vasconcelles, M.D. as a new Class III director with a term lasting until the 2026 annual stockholders’ meeting, and as a member of the Compensation Committee. Dr. Vasconcelles’ selection was independent of any outside arrangements, and he will be compensated with an annual cash retainer and stock options as per the company’s Compensation Policy. His compensation includes a $40,000 annual retainer, additional committee service fees, and significant stock options that vest over time, with full vesting upon a change in control.

For an in-depth examination of KURA stock, go to TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskKura Oncology Advances Cancer Treatment Pipeline
TheFlyKura Oncology reports Q3 EPS (63c), consensus (63c)
TheFlyKura Oncology to present updated data from KOMET-007 trial
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App